Experience with UroBest in Patients with Acute Cystitis
Study Overview
AIM: This study aimed to assess how effective and safe UroBest is for treating acute cystitis compared to similar products.
Methods
The study involved 90 patients aged 18 to 49 with acute cystitis. They were treated at various clinical sites in Russia. All patients received Fosfomycin trometamol (3g once at night). They were divided into three groups:
- Group 1: Received UroBest (1 sachet daily for 7 days) and NefroBest-N (1 capsule twice daily for 1 month).
- Group 2: Received UroBest (1 sachet daily for 7 days).
- Group 3: Received Uronext (1 sachet daily for 7 days).
The study monitored various health parameters, quality of life, pain levels, and any side effects.
Results
The results showed that using UroBest with plant extracts improved all health parameters, except for the white blood cell count. The best improvements were seen in Group 1, followed by Group 2. One patient in Group 3 experienced a side effect, but it resolved on its own.
Conclusion
UroBest is effective and safe. Combining UroBest with NefroBest-N showed better results in lab tests and patient health compared to using UroBest alone or with Uronext.
Enhancing Clinical Trials with Technology
Clinical trials are essential for creating safe and effective treatments. It’s vital to apply these findings in everyday medical practice. Our AI platform, DocSym, helps by gathering ICD-11 standards, clinical protocols, and research into one easy-to-use resource for healthcare providers.
Streamlining Healthcare Operations
In today’s healthcare landscape, efficiency is key. Our mobile apps assist with scheduling, treatment monitoring, and telemedicine, simplifying patient care management and expanding digital services.
Improving Patient Outcomes
By leveraging AI, clinics can optimize their workflows, enhance patient outcomes, and reduce paperwork. Discover how we can assist you at aidevmd.com.
